7.80
-0.035(-0.45%)
Currency In USD
| Previous Close | 7.83 |
| Open | 7.8 |
| Day High | 8.13 |
| Day Low | 7.78 |
| 52-Week High | 12.73 |
| 52-Week Low | 4.02 |
| Volume | 521,362 |
| Average Volume | 1.3M |
| Market Cap | 415.87M |
| PE | 2.98 |
| EPS | 2.62 |
| Moving Average 50 Days | 7.73 |
| Moving Average 200 Days | 7.4 |
| Change | -0.04 |
If you invested $1000 in Emergent BioSolutions Inc. (EBS) 10 years ago, it would be worth $239.85 as of September 17, 2025 at a share price of $7.795. Whereas If you bought $1000 worth of Emergent BioSolutions Inc. (EBS) shares 5 years ago, it would be worth $76.7 as of September 17, 2025 at a share price of $7.795.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
GlobeNewswire Inc.
Sep 15, 2025 12:35 PM GMT
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Ad
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
GlobeNewswire Inc.
Sep 09, 2025 11:30 AM GMT
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Liv
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
GlobeNewswire Inc.
Sep 02, 2025 11:40 AM GMT
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Ad